Antisense Oligonucleotide Therapeutics Market Size, Share & Trends Analysis Report, Analysis Report By By ASO Generation (First-Generation, Second-Generation, Third-Generation, Next-Generation), By Phase of Development, By Route of Administration, By Type of Therapy, By Indications, and By Drug Type, By Region, Forecasts, 2024-2031

Chapter 1.          Methodology and Scope

1.1.        Research Methodology

1.2.        Research Scope & Assumptions

Chapter 2.          Executive Summary

Chapter 3.          Global Antisense Oligonucleotides Market Snapshot

Chapter 4.          Global Antisense Oligonucleotides Market Variables, Trends & Scope

4.1.        Market Segmentation & Scope

4.2.        Drivers

4.3.        Challenges

4.4.        Opportunities

4.5.        Trends

4.6.        Investment and Funding Analysis

4.7.        Industry Analysis – Porter’s Five Forces Analysis

4.8.        USFDA Approved Antisense Oligonucleotide Products

4.9.        Clinical Trial Analysis

4.10.     Key Merger & Acquisitions, Partnership in the Market

4.11.     Competitive Landscape & Market Share Analysis

4.12.     Impact of Covid-19 Analysis

Chapter 5.          Market Segmentation 1: By Type of Therapy, Estimates & Trend Analysis

5.1.        By Type of Therapy, & Market Share, 2023 & 2031

5.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Type of Therapy:

5.2.1.    Monotherapy

5.2.2.    Combination Therapy

5.2.3.    Both

Chapter 6.          Market Segmentation 2: By Route of Administration Estimates & Trend Analysis

6.1.        By Route of Administration & Market Share, 2023 & 2031

6.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Route of Administration:

6.2.1.    Subcutaneous

6.2.2.    Intravenous

6.2.3.    Intrathecal

6.2.4.    Intravitreal

6.2.5.    Others

Chapter 7.          Market Segmentation 3: By Phase of Development Estimates & Trend Analysis

7.1.        By Phase of Development & Market Share, 2023 & 2031

7.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Phase of Development:

7.2.1.    Commercial

7.2.2.    Clinical

7.2.3.    Preclinical

7.2.4.    Discovery Stage

Chapter 8.          Market Segmentation 4: By ASO Generation Estimates & Trend Analysis

8.1.        By ASO Generation & Market Share, 2023 & 2031

8.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By ASO Generation:

8.2.1.    First-Generation

8.2.2.    Second-Generation

8.2.3.    Third-Generation

8.2.4.    Next-Generation

Chapter 9.          Market Segmentation 5: By Drug Type Estimates & Trend Analysis

9.1.        By Drug Type & Market Share, 2023 & 2031

9.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Drug Type:

9.2.1.    Eleplinsen

9.2.2.    Nusinersen

9.2.3.    Inotersen

9.2.4.    Volanesorsen

9.2.5.    Golodirsen

9.2.6.    Viltolarsen

9.2.7.    Casimersen

9.2.8.    Tofersen

9.2.9.    Others

Chapter 10.        Market Segmentation 6: By Indication Estimates & Trend Analysis

10.1.     By Indication & Market Share, 2023 & 2031

10.2.     Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Indication:

10.2.1.  Duchenne Muscular Dystrophy

10.2.2.  Spinal Muscular Atrophy

10.2.3.  Transthyretin Amyloidosis

10.2.4.  Familial Chylomicronemia Syndrome

10.2.5.  Amyotrophic Lateral Sclerosis

10.2.6.  Others

Chapter 11.        Antisense Oligonucleotides Market Segmentation 7: Regional Estimates & Trend Analysis

11.1.     North America

11.1.1.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2019-2031

11.1.2.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031

11.1.3.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2019-2031

11.1.4.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2019-2031

11.1.5.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2019-2031

11.1.6.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2019-2031

11.1.7.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2019-2031

11.1.7.1.             U.S.

11.1.7.2.             Canada

11.2.     Europe

11.2.1.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2019-2031

11.2.2.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031

11.2.3.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2019-2031

11.2.4.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2019-2031

11.2.5.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2019-2031

11.2.6.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2019-2031

11.2.7.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2019-2031

11.2.7.1.             Germany

11.2.7.2.             U.K.

11.2.7.3.             France

11.2.7.4.             Italy

11.2.7.5.             Spain

11.2.7.6.             Rest of Europe

11.3.     Asia Pacific

11.3.1.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2019-2031

11.3.2.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031

11.3.3.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2019-2031

11.3.4.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2019-2031

11.3.5.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2019-2031

11.3.6.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2019-2031

11.3.7.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2019-2031

11.3.7.1.             Japan

11.3.7.2.             China

11.3.7.3.             India

11.3.7.4.             Australia

11.3.7.5.             South Korea

11.3.7.6.             Southeast Asia

11.3.7.7.             Hong Kong

11.3.7.8.             Rest of Asia Pacific

11.4.     Latin America

11.4.1.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2019-2031

11.4.2.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031

11.4.3.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2019-2031

11.4.4.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2019-2031

11.4.5.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2019-2031

11.4.6.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2019-2031

11.4.7.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2019-2031

11.4.7.1.             Brazil

11.4.7.2.             Mexico

11.4.7.3.             Rest of Latin America

11.5.     Middle East & Africa

11.5.1.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2019-2031

11.5.2.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031

11.5.3.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2019-2031

11.5.4.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2019-2031

11.5.5.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2019-2031

11.5.6.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2019-2031

11.5.7.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2019-2031

11.5.7.1.             GCC Countries

11.5.7.2.             South Africa

11.5.7.3.             Rest of MEA

Chapter 12.        Competitive Landscape

12.1.     Major Mergers and Acquisitions/Strategic Alliances

12.2.     Company Profiles

12.2.1.  Sarepta Therapeutics

12.2.2.  Biogen

12.2.3.  Alnylam Pharmaceuticals, Inc

12.2.4.  Antisense Therapeutics Limited

12.2.5.  Sarna Therapeutics GmbH

12.2.6.  Arrowhead Pharmaceuticals, Inc.

12.2.7.  Atlantic Pharmaceuticals, Inc.

12.2.8.  Enzo Pharmaceuticals, Inc.

12.2.9.  Bio-Path Holdings, Inc.

12.2.10.              Gene Signal International SA

12.2.11.              GlaxoSmithKline plc

12.2.12.              Gerona Corporation

12.2.13.              Gradualist

12.2.14.              ICO Therapeutics

12.2.15.              Aptos Biosciences

12.2.16.              Marina Biotech

12.2.17.              mirage Therapeutics, Inc.

12.2.18.              Synodic, Inc.

12.2.19.              Oncogene Pharmaceuticals Inc.

12.2.20.              Pharm axis Ltd

12.2.21.              Regulus Therapeutics Inc., Reran Pharmaceuticals, Inc.

12.2.22.              RI Pharmaceuticals

12.2.23.              Ionis Pharmaceuticals

12.2.24.              ProQR Therapeutics

12.2.25.              Sterna Biologicals

12.2.26.              Wave Life Sciences

12.2.27.              Other Prominent Players

Segmentation of Antisense Oligonucleotide Therapeutics Market-

Antisense Oligonucleotides Therapeutics Market By Type of Therapy

• Monotherapy
• Combination Therapy
• Both

Antisense Oligonucleotides Therapeutics Market By ASO Generation

• First-Generation
• Second-Generation
• Third-Generation
• Next-Generation

Antisense Oligonucleotides Therapeutics Market By Phase of Development

• Commercial
• Clinical
• Preclinical
• Discovery Stage

Antisense Oligonucleotides Therapeutics Market By  Route of Administration

• Subcutaneous
• Intravenous
• Intrathecal
• Intravitreal
• Others

Antisense Oligonucleotides Therapeutics Market By Indications

• Duchenne Muscular Dystrophy
• Spinal Muscular Atrophy
• Transthyretin Amyloidosis
• Familial Chylomicronemia Syndrome
• Amyotrophic Lateral Sclerosis
• Others

Antisense Oligonucleotides Therapeutics Market By Drug Type

• Eleplinsen
• Nusinersen
• Inotersen
• Volanesorsen
• Golodirsen
• Viltolarsen
• Casimersen
• Tofersen
• Others

Antisense Oligonucleotides Therapeutics Market By Region-

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

• Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
• External and internal proprietary databases, regulatory databases, and relevant patent analysis
• Statistical databases, National government documents, and market reports
• Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

• Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
• Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
• Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
• End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.